autologous stem cell therapy for Diabetes type 2, insulin dependent. Protocol developed by Dr Sunil Waghmare of Spectrum cell clinic, Mumbai
More here:
stem cell therapy Diabetes type 2 insulin dependent - Video
Stem cell therapy patient Trish Stressman discusses her recovery from spinal cord injury after undergoing stem cell treatments at the Stem Cell Institute in Panama City, Panama. Ms. Stressman has regained control of her core and is now able to stand and walk with a walker.
See more here:
Stem Cells for Spinal Cord Injury: Community Outreach San Diego 2011 - Trish Stressman - Video
Eye-cup morphogenesis of ESC-derived retinal tissues in 3D live imaging.
Original post:
Stem cells spontaneously form eye-like structure - Video
"Your twin daughters have an extremely rare, fatal disease called Niemann Pick Type C and there's nothing you can do for them".
See the article here:
Stem Cell Banking: The Perspective of an iPS Donor Family - Video
Fintan Walton talks to Gary Rabin, Chairman
Continued here:
Advanced Cell Technologies: Human Embryonic Stem Cell Trials - Video
orlive.uwhealth.org Researcher, Dr. Timothy Kamp, discusses the depth and breadth of stem cell research at the UW.
Read more here:
Latest Update on Stem Cell Research at UW - Dr. Timothy Kamp - Video
"Becky" recently had stem cell therapy at Western Veterinary Clinic in South Bend, IN. This is a video about her story.
Read the original:
"Becky's" Stem Cell Therapy Story - Video
A year ago, 9-year-old Kenneth Kelley couldn't read.
Read the original here:
Stem Cell Treatment Doing Wonders For Autistic Boy - Video
"Becky" recently had stem cell therapy at Western Veterinary Clinic in South Bend, IN. This is a video about her story.
Read more:
"Becky's" Stem Cell Therapy Story - Video
Millie Jimenez discusses her twin boys' improvements after they both underwent stem cell therapy for autism at the Stem Cell Institute in Panama City, Panama. One of the boys, who was non-verbal prior to treatment is now speaking in English and Spanish. The other has stopped stimming and both are now making a "more affectionate" connection with their mother.
Visit link:
Stem Cell Treatment for Autism: Community Outreach Miami, Florida - May 2011 - Video
autologous stem cell therapy for Diabetes type 2, insulin dependent. Protocol developed by Dr Sunil Waghmare of Spectrum cell clinic, Mumbai
Read the original post:
stem cell therapy Diabetes type 2 insulin dependent - Video
Stem Cell Therapy for Dystonic Cerebral Palsy done at Neurogen Brain and Spine Institute Pvt.
Excerpt from:
Pre Post n 6 Months Post Stem Cell Therapy of Dystonic Cerebral Palsy - Video
see http://www.cellmedicine.com
Read the original post:
Stem Cell Therapy for Critical Limb Ischemia - Video
(HealthDay News) -- New research appears to dash hopes that people who consume more vitamin D might be at less risk of developing several less-common types of cancer.
Researchers found no link between higher blood levels of vitamin D and lower rates of non-Hodgkin lymphoma or cancers of the endometrium, esophagus, stomach, kidney, ovary and pancreas.
Vitamin D is obtained by the body through exposure to sunlight, certain foods such as oily fish, fortified foods and nutritional supplements.
Authors of a new study analyzed blood samples drawn from more than 12,000 men and women in 10 studies. The previous studies followed the patients for as long as 33 years, allowing researchers to determine if they developed cancer.
"We did not see lower cancer risk in persons with high vitamin D blood concentrations compared to normal concentrations for any of these cancers," said study co-investigator Dr. Demetrius Albanes of the U.S. National Cancer Institute in an institute news release. "And, at the other end of the vitamin D spectrum, we did not see higher cancer risk for participants with low levels."
However, the researchers did find that people with high levels of vitamin D were more likely to develop pancreatic cancer. It's not clear if there's a cause-and-effect relationship, and the study authors called for more research to assess the possible association. Read more...
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
The California stem cell agency is huddling with industry, scientists and public as it wades through a revision of its strategic plan to determine how to spend its remaining $1.4 billion before the cash runs out.
CIRM officials have held at least 10 meetings with a variety of groups, including three public sessions. The next public hearing is Thursday in Los Angeles at the CIRM board meeting.
The revision comes as the agency wrestles with the increasing need to generate results that will resonate with California voters. CIRM's original $3 billion, which consists of cash borrowed by the state, will run out in roughly 2017. The agency is considering mounting a ballot campaign for another multibillion dollar bond measure. The agency is also under examination by the prestiguous Institute of Medicine and is likely to hear recommendations for changes from that report next fall.
Ellen Feigal, senior vice president for research and development, summarized stakeholder comments so far on CIRM's plans in a 13-page documment prepared for the meeting at Cedars-Sinai. She identified several key themes from stakeholders, including the need to find "alternate funding resources," presumably non-public financing. Feigal also cited a need to make the grant funding process more transparent, apparently reflecting complaints from industry. But she noted that stakeholders have said the agency has made "great initial progress" in its first seven years.
Here are four of the five themes Feigal identified. The fifth dealt mentioned CIRM's progress.
Feigal also mentioned a number of recommendations from industry, which has been less than happy with its meager share of CIRM funding. The suggestions included creation of "communications bridges" and better communication of the funding process. Also recommended was a "split review process – (academic vs. industry)" and a faster approval process that takes into account the high "burn rate" of cash at biotech companies. Another industry suggestion was creation of an "in-house champion" to help businesses navigate the CIRM funding process.
Feigal will come back to the board in January with a draft revision. It is scheduled to be approved March 21. The final plan will be shipped off to the IOM panel studying CIRM. It is scheduled to conclude its work next fall.
Interested parties can email their comments on the plan to CIRM (info@cirm.ca.gov) or speak at CIRM board meetings. The specific address for Thursday's meeting can be found on the agenda. A teleconference location is also available at UC San Francisco, where members of public can take part.
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
The $3 billion California stem cell agency has played a role in bringing two star researchers to the Golden State through its $44 million recruitment program and is about ready to bring in a third.
Next Thursday in Los Angeles, CIRM's governing board is expected to approve a $5.6 million grant to an unidentified scientist to lure him or her to an unidentified California institution.
The funds will go for the researcher's efforts to develop "a regeneration-based functional restoration treatment for spinal cord injury," according to a summary of reviewer comments on the CIRM web site. The grant was scored at 86 by scientific reviewers.
The summary quoted the researcher as saying,
"We recently made breakthrough discoveries in identifying key biological mechanisms stimulating the re-growth of injured axons in the adult nervous system, which led to unprecedented extents of axon regeneration in various CNS injury models. While our success was compelling, we found that many regenerated axons were stalled at the lesion sites by the injury-induced glial scars. Furthermore, it is unclear whether the regenerated axons can form functional synaptic connections when they grow into the denervated spinal cord. This proposed research program is aimed at solving these obstacles by using human stem cell technologies."
The summary said,
"The PI was described by reviewers as a superb scientist and emerging leader with outstanding accomplishments and exceptional promise. The candidate has already made key contributions to the understanding of mechanism underlying axonal regeneration that have significantly advanced the field of neuroregeneration. He/she has been extremely productive, publishing a number of seminal papers in the highest profile journals including Science, Nature, Neuron and Nature Neuroscience."
The stem cell agency's recruitment efforts have helped to bring Peter Coffey ($4.9 million from CIRM)from the UK to UC Santa Barbara and Robert Wechsler-Reya ($6 million)- to Sanford Burnham in La Jolla from Duke University.
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
A Canadian bioethicist is raising ethical questions about Geron's hESC trial that have implications for the attempt by the California stem cell agency to salvage the once-vaunted effort.
Writing yesterday on the Hastings Center Bioethics Forum, Francoise Baylis of Dalhousie University said,
"It is one thing to close a trial to further enrollment for scientific reasons, such as a problem with trial design, or for ethical reasons, such as an unanticipated serious risk of harm to participants. It is quite another matter to close a trial for business reasons, such as to improve profit margins."
Geron last month said it was ending the trial because of financial reasons and to pursue development of its cancer treatments. CIRM awarded Geron a $25 million loan just last May and was surprised by the Geron move. The $3 billion state research program is now attempting to find a buyer/partner for Geron's hESC business.
Baylis noted that Stephen Kelsey, chief medical officer of the Menlo Park, Ca., firm, has been quoted as saying that the results of Geron trial – now with five patients instead of the projected 10 – "will be a fair reflection of what would have happened if we had completed the study."
Baylis wrote,
"This statement is deeply problematic, however."
Baylis, a professor and the Canada Research Chair in the departments of philosophy and of obstetrics and gynecology at Dalhousie, continued,
"No clinical trial should involve too few or too many participants. It is important that the trial not be underpowered and thus unable to generate scientific knowledge. It is equally important than no more research participants than necessary be exposed to potential research risks. If only five participants were needed to generate the scientific knowledge, then why would Geron and the F.D.A. have agreed to expose additional persons to the potential harms of trial participation?
"On the other hand, if Kelsey’s statement is false, and the findings from five research participants will be underpowered, then they may have been exposed to the potential harms of trial participation without the potential for benefit in the form of scientific knowledge."
She concluded,
"In either case, the scenario forces us to consider what measures should be taken with respect to future trials funded in the private sector so that participants are not left stranded. Perhaps regulators and institutional review boards should critically examine whether a company has both the financial (and other) resources and the will to complete a trial under review before granting regulatory or ethics approval. If there are doubts about this, then either the trial should not be approved, or there should be stringent disclosure requirements so that prospective research participants are aware of the possibility that research may stop mid-trial for financial reasons."
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
